Actuate Therapeutics

Q2 FY2026 EarningsQ2 FY2026 performance was mixed compared to consensus: while R&D and G&A expense control led to a beat in operating loss ($4.91M vs. $5.61M expected), Normalized EPS missed by $0.0025 due to share count expansion. Revenue remained at zero in line with clinical-stage expectations. The company highlighted a liquidity crunch, with cash reserves of $4.43M only sufficient to fund operations through September 2026, posing a significant 'going concern' risk despite positive Phase 2 mPDAC data.